Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Jessica L Maes"'
Autor:
Michael T Schweizer, Kathleen Haugk, Jožefa S McKiernan, Roman Gulati, Heather H Cheng, Jessica L Maes, Ruth F Dumpit, Peter S Nelson, Bruce Montgomery, Jeannine S McCune, Stephen R Plymate, Evan Y Yu
Publikováno v:
PLoS ONE, Vol 13, Iss 6, p e0198389 (2018)
BACKGROUND:Niclosamide, an FDA-approved anti-helminthic drug, has activity in preclinical models of castration-resistant prostate cancer (CRPC). Potential mechanisms of action include degrading constitutively active androgen receptor splice variants
Externí odkaz:
https://doaj.org/article/f9580013a67f4ac696bef5949286bdea
Autor:
Michael T Schweizer, Kathleen Haugk, Jožefa S McKiernan, Roman Gulati, Heather H Cheng, Jessica L Maes, Ruth F Dumpit, Peter S Nelson, Bruce Montgomery, Jeannine S McCune, Stephen R Plymate, Evan Y Yu
Publikováno v:
PLoS ONE, Vol 13, Iss 8, p e0202709 (2018)
[This corrects the article DOI: 10.1371/journal.pone.0198389.].
Externí odkaz:
https://doaj.org/article/b39a0a762e51418db081ff1e29182883
Autor:
Ruth Dumpit, Peter S. Nelson, Jeannine S. McCune, Jožefa S. McKiernan, Kathleen Haugk, Michael T. Schweizer, Bruce Montgomery, Evan Y. Yu, Heather H. Cheng, Roman Gulati, Stephen R. Plymate, Jessica L. Maes
Publikováno v:
PLoS ONE, Vol 13, Iss 6, p e0198389 (2018)
PLoS ONE
PLoS ONE
Background Niclosamide, an FDA-approved anti-helminthic drug, has activity in preclinical models of castration-resistant prostate cancer (CRPC). Potential mechanisms of action include degrading constitutively active androgen receptor splice variants
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3abd07eafeb035dba6389a9311963922
https://doi.org/10.1371/journal.pone.0198389
https://doi.org/10.1371/journal.pone.0198389
Autor:
Evan Y. Yu, Jessica L. Maes, Robert B. Montgomery, Kathleen Haugk, Heather H. Cheng, Ruth Dumpit, Peter S. Nelson, Stephen R. Plymate, Michael T. Schweizer
Publikováno v:
Journal of Clinical Oncology. 35:264-264
264 Background: AR-Vs are truncated androgen receptor (AR) isoforms that lack the ligand-binding domain (LBD) and are associated with resistance to drugs targeting the ligand-AR LBD interaction (e.g. abiraterone [Abi], enzalutamide [Enza]). Preclinic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5ae1c96efbe852846cdb8f70c437c043
https://doi.org/10.1200/jco.2017.35.6_suppl.264
https://doi.org/10.1200/jco.2017.35.6_suppl.264